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Introduction
The pairwise comparisons reported within each randomized 
controlled trial are being documented in study-based registers1. 
This lends itself to accurate indexing and enumeration of these 
comparisons within the studies and then subsequent supply of 
immediate, highly sensitive and highly specific search results 
to those wishing to investigate one or more particular compari-
sons within systematic reviews and meta-analyses or overviews 
and network meta-analysis1,2.
To gain a perspective on the absolute effectiveness of a treatment 
it is ideal to compare all the existing medications with placebo 
and for relative effects with each other in pairwise comparison 
trials. However, some of pairwise comparisons of the medica-
tions have not been tested within trials at all. Finally, even if some 
of the possible pairwise comparisons have been directly tested 
within trials not all may be eligible for inclusion in a network 
meta-analysis3. This leaves a gap between the research has been 
done and the research that should or could have been undertaken 
and finding this highlights gaps in the fair testing of treatments4.
A two-arm trial will generate one pairwise comparison. A three-
arm trial, however. will generate three, and a six-arm study, 15 
pairwise comparisons. It is easy to lose track of how many com-
parisons one study can generate. This is more likely when it 
comes to the many direct, indirect or mixed comparisons within 
a network. This paper describes a simple formula for enumerating 
the possible number of comparisons within a single trial or planned 
network meta-analysis in advance.
Methods
The formula
The formula below solves this where n is the number of arms 
in a single study or network and N is the number of pairwise 
comparisons:
                                        
*( ( 1)) / 2N n n= −
Where n > 0;
n is a natural number;
Then every intervention is compared to every other intervention 
except itself so: n*(n-1);
Because N is a bidirectional comparison (X vs. Y = Y vs. X) 
so: (n*(n-1))/2;
N is a triangular number.
A visual proof of a network of five interventions and (5*(5-1))/2=10 
pairwise comparisons is presented in Figure 1.
Adding any new intervention to the trial or network will 
create n-1 new pairwise comparisons. For example, where there 
are 6 arms in a trial—or 6 nodes in network meta-analysis—there 
will be (6*(6-1))/2=15 comparisons; adding a new intervention 
(6+1=7) will create 7-1=6 new pairwise direct comparisons in 
Figure 1. Network of five interventions and (5*(5-1))/2=10 pairwise comparisons.
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an individual trial and 6 direct or indirect comparisons in a net-
work meta-analysis. Although this formula has been used for 
other purposes such as Metcalfe’s law in telecommunication, 
its use in the current context is novel.
Testing the formula: working back from existing network 
meta-analyses
We used the open data5 from our previously published net-
work meta-analysis6 to re-create and enumerate the comparisons 
within the network. Using the direct comparisons reported in 
the trials within the network, we applied the formula and then 
compared the number of potential or expected comparisons 
(formula-derived) and the actual or observed number reported 
within the network analysis.
Results
Number of direct and indirect comparisons
We built a small study-based register based—thus avoiding the 
pitfall of multiple counting—containing all 133 included studies 
in our previous network meta-analysis6,7. These trials reported 
comparisons from 8 interventions. Using our formula, 8 inter-
ventions should create 28 unique comparisons: (8*(8-1))/2=28 
(Figure 2).
Reported comparisons within the trials
We extracted the separate intervention arms from the open data 
to re-create the direct comparisons from within trials. There 
trials had either two or three arms so each study could create 
either two or three comparisons. As a result the 133 studies 
had 163 comparisons, the majority of which were duplicated. 
After removing these duplicates, this created 16 unique direct 
comparisons with between 1 and 47 studies per comparison for 
8 interventions (Table 1). These 16 observed comparisons are 
57% of the 28 expected by use of the formula above.
Direct comparisons eligible for network meta-analysis
Among five networks reported in the final paper, the number of 
comparisons in these five network meta-analyses, however, varies 
from 6 (for 3 networks) to 11 (for 1 network) and 13 (for 1 net-
work) (Figure 3). As visualized in Figure 3, only 21.42% to 46.42% 
of comparisons were eligible for pairwise meta-analysis (Table 2).
Comparisons in network meta-analysis plots
From Figure 3 we can calculate that about 42% of comparisons 
expected though use of the formula have not been tested directly 
in trials. This is a direct evidence-gap. The number of missing 
comparisons varies between nine out of 15 in three networks 
with six interventions, 17 out of 28 in one network with eight 
interventions, and 15 out of 28 in another network with eight 
interventions ( Figure 3). However, all 28 comparisons expected 
by use of the formula were utilized and reported within the net-
work meta-analysis. It is possible that some of the comparisons 
predicted by the formula would have been deemed ineligible— 
either by adherence to a network review protocol or though post 
hoc exclusions—but this was not the case in this particular review 
Figure 4
Discussion
This formula can be employed when estimating the total number 
of comparisons (direct and indirect combined) theoretically 
possible within a proposed network meta-analysis. It would be 
possible that there would sometimes be a discrepancy between 
Figure 2. All the possible unique bidirectional comparisons of 8 ADHD medications. Only 16 out of 28 comparisons have been directly 
compared in trials (green lines).
( ).
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Figure 3. Direct and indirect comparisons in the network meta-analysis of 8 interventions for primary outcome. (Dark lines are eligible 
comparisons for pairwise meta-analysis, added dotted blue lines show indirect comparisons). This image has been modified from Cotese 
et al. 20186 under Creative Commons Attribution License (CC BY).
Page 5 of 8
F1000Research 2019, 8:38 Last updated: 09 JAN 2019










Direct Indirect Eligible Ineligible
   Formula √ √ √ √ 28=(8*(8-1))/2 100.00
   Randomised trials √ × √ √ 16 (Table 1) 57.14
   Pairwise meta-analysis √ × √ × 6-13 (Figure 3)* 21.42 to 46.42
   Network meta-analysis √ √ √ √ 28 (Figure 2) 100.00
* There are five networks in Figure 3 and each has 6, 11, or 13 eligible comparisons. Three out of 16 comparisons 
from trials have not been included in any of five network plots.
the number of comparisons theoretically possible and those 
actually employed within any given network meta-analysis. The 
formula would highlight this for researchers and readers and, 
before and after analyses, facilitate descriptions of why particular 
comparisons have not been included.
Conclusion
The formula produces an accurate enumeration of the potential 
comparisons within a single trial or network meta-analysis.
Any shortfall between the full potential of the data and the 
actual number of comparisons within a network meta-analysis 
Figure 4. Venn diagram showing the coverage of comparisons by the network meta-analysis (from formula), and pairwise 
meta-analysis (from network plots), and trials (from study-based register).
should be possible to explain through reference to pre-stipulated 
eligibility criteria or post hoc exclusions.
Data availability
The data analyzed in the present study have been published 
previously6,7.
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